These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 23873291

  • 21. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 22. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.
    Int Clin Psychopharmacol; 2011 Mar 04; 26(2):75-83. PubMed ID: 21102344
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan 04; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 26. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Jan 04; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 27. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E.
    Int Clin Psychopharmacol; 2009 May 04; 24(3):133-8. PubMed ID: 19318972
    [Abstract] [Full Text] [Related]

  • 28. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS, Loft H, Dragheim M.
    Eur Neuropsychopharmacol; 2012 Jul 04; 22(7):482-91. PubMed ID: 22209361
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
    Arnold LM, Zhang S, Pangallo BA.
    Clin J Pain; 2012 Jul 04; 28(9):775-81. PubMed ID: 22971669
    [Abstract] [Full Text] [Related]

  • 32. Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine.
    Tokuoka H, Nishihara M, Fujikoshi S, Yoshikawa A, Kuga A.
    Neuropsychiatr Dis Treat; 2017 Jul 04; 13():2457-2467. PubMed ID: 29026309
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM, Myers AL, Marangell LB, Ahl J, Prakash A, Thase ME, Kornstein SG.
    Hum Psychopharmacol; 2012 Jan 04; 27(1):47-56. PubMed ID: 22241678
    [Abstract] [Full Text] [Related]

  • 35. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun 04; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 36. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Jun 04; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun 04; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 39. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
    Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C.
    J Psychiatr Res; 2011 Jun 04; 45(6):748-55. PubMed ID: 21511276
    [Abstract] [Full Text] [Related]

  • 40. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Jun 04; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.